UPDATE 4-Cell Therapeutics drug draws US FDA staff concerns
* FDA staff raise issues with safety, effectiveness
* Pixantrone to be reviewed by advisory panel Wednesday
* Company says drug works, side effects manageable
* Shares fall nearly 40 pct (Updates shares, adds details on Novartis option)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters